+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 60 Actively Recruiting clinical trials

O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.

Age: 18Years - 75YearsAll GendersPhase 2
58 locations
E

Actively Recruiting

Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.

Age: 18Years - 130YearsAll GendersPhase 3
89 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness of angiotensin receptor-neprilysin inhibitor ARNi therapy compared to antihypertensive monotherapy in lowering blood pressure among adults with hypertension in the United Arab Emirates. The study focuses on patients diagnosed with hypertension and aims to see how these treatments impact blood pressure control in everyday clinical settings. The study includes two groups one group starts or switches to ARNi treatment sacubitrilvalsartan, and the other begins antihypertensive monotherapy with either an ACE inhibitor, an ARB, or a calcium channel blocker. Patients will be observed as they receive these therapies according to their physicians direction. Participants will have their blood pressure measured at the start and during follow-up visits, with primary measurement focused on the change in mean sitting systolic blood pressure from baseline to week 4. Additional measures include diastolic blood pressure, pulse pressure, and the proportion of patients reaching target blood pressure at weeks 4 and 12. The study will continue until August 2027, with assessments occurring at these defined timepoints to monitor treatment effects and safety.

Age: 18Years - 99YearsAll Genders
4 locations
R

Actively Recruiting

Researchers are evaluating luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. This observational study aims to understand how luspatercept affects the need for blood transfusions and hemoglobin levels in real-world clinical settings. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have started luspatercept treatment within the past year. Participants receive luspatercept as prescribed according to the product label, with no experimental intervention assigned by the study. The study observes ongoing treatment and collects data retrospectively and prospectively, following participants for up to 144 weeks. Key measurements include changes in transfusion burden, pre-transfusion hemoglobin, and iron levels, among other clinical and healthcare utilization outcomes. During the study, participants provide signed consent and allow researchers to collect medical data relevant to their treatment with luspatercept. Researchers monitor transfusion visits, hemoglobin levels, treatment duration, dose adjustments, and other health indicators. The study includes comprehensive data collection on participants disease characteristics, comorbidities, and treatment history, aiming to provide a detailed understanding of luspatercepts use over nearly three years.

Age: 18Years +All Genders
13 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
A

Actively Recruiting

Researchers are evaluating EP0031 Lunbotinib, a next-generation selective RET inhibitor, in adults with advanced RET-altered non-small cell lung cancer NSCLC. This Phase III study aims to find the optimal dose and assess the safety, side effects, and effectiveness of EP0031 alone and in combination with standard chemotherapy. The study addresses a critical need as no approved RET-targeted treatments exist for patients whose cancer progresses after first-generation selective RET inhibitors SRIs. Participants receive EP0031 capsules once daily at the recommended dose alongside platinum-based doublet chemotherapy on Day 1 of each 21-day cycle, for up to four cycles. Following this, participants continue EP0031 with pemetrexed maintenance until disease progression, unacceptable side effects, or withdrawal. The study includes two groups treatment-naive patients and a now-closed cohort previously treated with a first-generation SRI. The Phase 1 dose escalation has completed, and the study is currently in Phase 2. During the trial, participants undergo regular assessments including tumor measurements using RECIST v1.1 criteria, safety and tolerability monitoring, and pharmacokinetic tests to measure drug levels in the body. Key outcomes include evaluating dose-limiting toxicities within the first 21 days and measuring overall response rates over 12 months. The study continues until March 2028, with ongoing observation of effects and side effects throughout treatment.

Age: 18Years +All GendersPhase 1Phase 2
52 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.

Age: 18Years - 65YearsAll GendersPhase 3
40 locations
S

Actively Recruiting

Researchers are evaluating a screening tool that uses retinal imaging to detect changes in the eye related to Alzheimers disease in adults with memory problems. The study focuses on individuals with mild memory complaints or mild cognitive impairment and aims to compare retinal scan results with blood tests to detect abnormal protein deposits associated with Alzheimers disease. Participants will undergo a retinal scan and blood test during a single visit. The retinal scan provides detailed images of the retina, while the blood test checks for a specific protein linked to early Alzheimers detection. This observational study lasts up to one month for each participant and involves no drug treatments. During the study visit, participants will have their retina scanned and blood drawn for testing. Researchers will measure how often the retinal scan and blood test results agree and will assess participant satisfaction with the retinal scan. The study is sponsored by Eli Lilly and Company and includes adults aged 55 and older with mild cognitive issues. Participants are monitored only during the one study visit, and no long-term treatment or follow-up is required.

Age: 55Years +All Genders
3 locations

1-10 of 60

1